澳大利亚医疗产品局(TGA)在最新的药物安全简报中指出胆碱酯酶抑制剂可增加晕厥、心动过缓和心脏起搏器植入的比例,晕厥还可致髋部骨折等跌伤[1]。胆碱酯酶抑制剂包括多奈哌齐,卡巴拉汀和加兰他敏等,澳洲药物福利计划将这类药物作为治疗轻度至中重度的阿尔茨海默病的基本用药, Australian Medical Products Agency (TGA) in the latest drug safety briefing pointed out that cholinesterase inhibitors can increase the proportion of syncope, bradycardia and pacemaker implantation, syncope can also cause hip injuries and other falls [1] . Cholinesterase inhibitors include donepezil, rivastigmine and galantamine, the Australian drug benefits plan to use these drugs as the basic treatment of mild to moderate Alzheimer’s disease,